TargetMol

IRBP acetate(211426-18-5 free base)

Product Code:
 
TAR-TP1120L
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-TP1120L-1mg1mg£177.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TP1120L-5mg5mg£313.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TP1120L-10mg10mg£434.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TP1120L-25mg25mg£671.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TP1120L-50mg50mg£914.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TP1120L-100mg100mg£1,211.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
IRBP(Interphotoreceptor Retinoid Binding Protein Fragment ) acetate is a 20-residue peptide, which is a major pathogenic epitope. It exists in the first homologous repeat of interstitial visual pigment Binding Protein peptide (IRBP 161-180) and can induce post-uveitis (EAU).
CAS:
TP1120L
Formula:
C105H161N25O31
Molecular Weight:
2269.55
Purity:
0.9554
SMILES:
0

References

Yang H, et al. Activation of liver X receptor alleviates ocular inflammation in experimental autoimmune uveitis. Invest Ophthalmol Vis Sci. 2014 Apr 28;55(4):2795-804. Tang J, et al. Autoimmune uveitis elicited with antigen-pulsed dendritic cells has a distinct clinical signatureand is driven by unique effector mechanisms: initial encounter with autoantigen defines diseasephenotype. J Immunol. 2007 May 1;178(9):5578-87. Cortes LM, et al. Inhibitory peptide analogs derived from a major uveitogenic epitope protect from antiretinalautoimmunity by inducing type 2 and regulatory T cells. J Leukoc Biol. 2008 Aug;84(2):577-85.